-
Mashup Score: 6PARTIQoL Trial: IMRT, Proton Therapy Offer Similar Efficacy, Quality of Life in Prostate Cancer | Cancer Nursing Today - 25 day(s) ago
Radiotherapy for localized prostate cancer can “achieve excellent quality of life with highly effective tumor control,” according to an ASTRO 2024 presentation.
Source: cancernursingtoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0Religious beliefs, lack of trust could explain Black patients’ hesitancy to join cancer trials - 28 day(s) ago
Spiritual beliefs and lack of trust in clinical research may influence Black individuals’ decisions about whether to participate in cancer trials, according to findings presented at American Society for Radiation Oncology Annual Meeting.In the cross-sectional descriptive study, researchers identified 138 individuals who had undergone definitive radiation treatment for gastrointestinal,
Source: www.healio.comCategories: General Medicine News, Oncologists1Tweet-
Spiritual beliefs and lack of trust in clinical research may influence Black individuals’ decisions about whether to participate in cancer trials, according to data presented at #ASTRO24. Healio spoke with a @UMmedschool medical student about the data. https://t.co/sR8i01Opnz
-
-
Mashup Score: 2
Learn about the Continuing Education Credits offered for the 2024 ASTRO Annual Meeting.
Source: www.astro.orgCategories: General Medicine News, Oncologists1Tweet-
Attention #ASTRO24 physicist & dosimetrist attendees: TODAY, Nov. 4, is the last day to claim MDCB and CAMPEP credits from the Annual Metting. Learn more here: https://t.co/6bVtvs1lkn @aapmHQ @med_dosimetry https://t.co/LhEDguXq5T
-
-
Mashup Score: 6
Concurrent administration of chemoradiation and immunotherapy did not improve survival for patients with limited-stage small cell lung cancer, according to a study presented at American Society for Radiation Oncology Annual Meeting.The findings follow those of the randomized phase 3 ADRIATIC trial, which showed durvalumab (Imfinzi, AstraZeneca) — a monoclonal antibody that binds to PD-L1
Source: www.healio.comCategories: General Medicine News, Oncologists1Tweet-
Healio spoke with @KHigginsMD of @cityofhope about data showing that concurrent administration of chemoradiation and immunotherapy did not improve survival for patients with limited-stage small cell lung cancer. @ASTRO_org #ASTRO24 https://t.co/fTIkDquMgc
-
-
Mashup Score: 6Liu’s Insights on Navigating the Fragility of Phase 3 Trials - 2 month(s) ago
Yufei Liu, MD, PhD, discussed the importance of careful data interpretation to accurately assess the efficacy of new treatment options in oncology.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
In an interview, Yufei Liu, MD, PhD, discussed the importance of careful data interpretation to accurately assess the efficacy of new treatment options in oncology. #ASTRO24 | @COH_RadOnc https://t.co/GwCcrdlfv3
-
-
Mashup Score: 6Interim Futility Results of NRG-HN005, A Randomized, Phase II/III Non-Inferiority Trial for Non-Smoking p16+ Oropharyngeal Cancer Patients - 2 month(s) ago
NRG-HN005 was a phase II/III randomized study comparing each of two experimental arm(s) against a control arm from RTOG 1016, in patients with p16+, non-smoking associated, locoregionally advanced oropharyngeal cancer. The phase II primary endpoint was non-inferiority (NI) of progression-free survival (PFS). The phase III trial would have included the experimental arm(s) found to be NI in phase II, with co-primary endpoints of NI PFS and superior quality of life.
Source: www.redjournal.orgCategories: General Medicine News, Hem/OncsTweet-
@DrLesterColl NRG HN 005 presented at #ASTRO24: no benefit of RT + nivolumab over RT + chemo for p16+ oropharyngeal cancer https://t.co/wDedd0Jl3k Thanks @CJTsaiMDPhD https://t.co/CNAcjnICxG https://t.co/uGyw8EDaph
-
-
Mashup Score: 4Concurrent Chemoradiation ± Atezolizumab (atezo) in Limited-Stage Small Cell Lung Cancer (LS-SCLC): Results of NRG Oncology/Alliance LU005 - 2 month(s) ago
Concurrent chemoradiation (cCRT) followed by prophylactic cranial irradiation (PCI) has been the standard of care for LS-SCLC for decades. NRG-LU005 (NCT03811002) tested the addition of atezo to cCRT in this open label, randomized phase III international trial. Here, results of the 2nd planned interim analysis are reported as recommended by the Data Monitoring Committee.
Source: www.redjournal.orgCategories: General Medicine News, Hem/OncsTweet-
NRG LU 005 presented at #ASTRO24: Chemoradiation with concurrent and consolidation atezolizumab did not improve survival in LS-SCLC https://t.co/ySRuOCoVNc Thanks @DrLesterColl https://t.co/KIPxGWzKRA https://t.co/eaTIbil9rc
-
-
Mashup Score: 17
In an interview with Targeted Oncology, Rupesh Kotecha, MD, discussed a machine learning tool designed to predict local failure after stereotactic radiosurgery for brain metastases.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Rupesh Kotecha, MD, (@Rrkotecha) discussed a machine learning tool designed to predict local failure after stereotactic radiosurgery for brain metastases. #ASTRO24 | @MiamiCancerInst @BHCancerCare @BaptistHealthSF https://t.co/3sw8dGfcBq
-
-
Mashup Score: 5Shorter course of radiation after mastectomy does not compromise breast reconstruction - 3 month(s) ago
Women who want breast reconstruction after mastectomy can undergo a shorter radiation therapy regimen without significantly increasing their risk for complications, according to results of a randomized phase 3 trial.Patients treated on a schedule 2 weeks shorter than standard of care had similar rates of complications and recurrence, findings presented during American Society for Radiation
Source: www.healio.comCategories: General Medicine News, Oncologists1Tweet-
Women who want breast reconstruction after mastectomy can undergo a shorter radiation therapy regimen without significantly increasing their risk for complications, according to data presented at #ASTRO24. @ASTRO_org Read more 👇 https://t.co/yvjbdnsC87
-
-
Mashup Score: 4PARTIQoL Trial: IMRT, Proton Therapy Offer Similar Efficacy, Quality of Life in Prostate Cancer | Cancer Nursing Today - 3 month(s) ago
Radiotherapy for localized prostate cancer can “achieve excellent quality of life with highly effective tumor control,” according to an ASTRO 2024 presentation.
Source: cancernursingtoday.comCategories: General Medicine News, Partners & KOLsTweet-
📰 IMRT and proton therapy offer "comparatively excellent" efficacy and quality of life for patients with localized prostate cancer, according to PARTIQoL results presented at #ASTRO24 by @drjefstathiou of @harvardmed, @MGHCancerCenter. ➡️ Read more: https://t.co/XBpUC2yTGp https://t.co/AMKMB8tnw9
-
📰 IMRT and proton therapy offer "comparatively excellent" efficacy and quality of life for patients with localized prostate cancer, according to PARTIQoL results presented at #ASTRO24 by @drjefstathiou of @harvardmed, @MGHCancerCenter. ➡️ Read more: https://t.co/XBpUC2yTGp https://t.co/AMKMB8tnw9